These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 23732750)

  • 1. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients.
    Hall RP; Streilein RD; Hannah DL; McNair PD; Fairley JA; Ronaghy A; Edhegard KD; Levesque MC
    J Invest Dermatol; 2013 Dec; 133(12):2786-2788. PubMed ID: 23732750
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients.
    Lourari S; Herve C; Doffoel-Hantz V; Meyer N; Bulai-Livideanu C; Viraben R; Maza A; Adoue D; Bedane C; Paul C
    J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1238-40. PubMed ID: 21054575
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab decreases without preference all subclasses of IgG anti-BP180 autoantibodies in refractory bullous pemphigoid (BP).
    Ronaghy A; Streilein RD; Hall RP
    J Dermatol Sci; 2014 Apr; 74(1):93-4. PubMed ID: 24461673
    [No Abstract]   [Full Text] [Related]  

  • 4. Refractory childhood pemphigoid successfully treated with rituximab.
    Fuertes I; Luelmo J; Leal L; Romaní J; Sánchez S; Mascaró JM
    Pediatr Dermatol; 2013; 30(5):e96-7. PubMed ID: 23278674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Remission of bullous pemphigoid after rituximab treatment in a psoriasis patient on regular low-dose methotrexate.
    Wang TS; Tsai TF
    Acta Derm Venereol; 2014 Jan; 94(1):108-9. PubMed ID: 23624752
    [No Abstract]   [Full Text] [Related]  

  • 6. Where does rituximab fit in the treatment of autoimmune mucocutaneous blistering skin disease?
    Nigam R; Levitt J
    J Drugs Dermatol; 2012 May; 11(5):622-5. PubMed ID: 22527431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of bullous pemphigoid with rituximab: critical analysis of the current literature.
    Shetty S; Ahmed AR
    J Drugs Dermatol; 2013 Jun; 12(6):672-7. PubMed ID: 23839185
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new approach on bullous pemphigoid therapy.
    Saouli Z; Papadopoulos A; Kaiafa G; Girtovitis F; Kontoninas Z
    Ann Oncol; 2008 Apr; 19(4):825-6. PubMed ID: 18325915
    [No Abstract]   [Full Text] [Related]  

  • 9. "Half-half" blisters in bullous pemphigoid successfully treated with adjuvant high-dose intravenous immunoglobulin.
    Pacheco D; Lopes L; Soares-Almeida L; Marques MS; Filipe P
    Acta Dermatovenerol Alp Pannonica Adriat; 2012 Sep; 21(3):59-61. PubMed ID: 23267874
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refractory bullous pemphigoid with fatal outcome in a young patient.
    Cruz MJ; Santos P; Morais P; Barreto F; Azevedo F
    Int J Dermatol; 2013 May; 52(5):601-2. PubMed ID: 23590375
    [No Abstract]   [Full Text] [Related]  

  • 11. Serum levels of BAFF are increased in bullous pemphigoid but not in pemphigus vulgaris.
    Asashima N; Fujimoto M; Watanabe R; Nakashima H; Yazawa N; Okochi H; Tamaki K
    Br J Dermatol; 2006 Aug; 155(2):330-6. PubMed ID: 16882171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dramatic exacerbation of bullous pemphigoid following rituximab and successful treatment with omalizumab.
    Maglie R; Antiga E; Quintarelli L; Verdelli A; Caproni M
    Eur J Dermatol; 2019 Apr; 29(2):213-215. PubMed ID: 30827944
    [No Abstract]   [Full Text] [Related]  

  • 13. Cost and Resource Use of Pemphigus and Pemphigoid Disorders Pre- and Post-Rituximab.
    Heelan K; Hassan S; Bannon G; Knowles S; Walsh S; Shear NH; Mittmann N
    J Cutan Med Surg; 2015; 19(3):274-82. PubMed ID: 25775641
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bullous Pemphigoid Successfully Treated with Rituximab].
    Silva N; Costa A; Salvador F; Serradeiro E
    Acta Med Port; 2017 Mar; 30(3):243-246. PubMed ID: 28550834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Memory B cells specific for the NC16A domain of the 180 kDa bullous pemphigoid autoantigen can be detected in peripheral blood of bullous pemphigoid patients and induced in vitro to synthesize autoantibodies.
    Leyendeckers H; Tasanen K; Bruckner-Tuderman L; Zillikens D; Sitaru C; Schmitz J; Hunzelmann N
    J Invest Dermatol; 2003 Mar; 120(3):372-8. PubMed ID: 12603849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early-onset neutropenia after rituximab therapy for bullous pemphigoid.
    Adler BL; Crew AB; Woodley DT
    Clin Exp Dermatol; 2019 Apr; 44(3):334-336. PubMed ID: 30151931
    [No Abstract]   [Full Text] [Related]  

  • 17. [Bullous pemphigoid and acquired haemophilia].
    Kluger N; Navarro R; Pallure V; Guillot B
    Ann Dermatol Venereol; 2011 May; 138(5):422-3. PubMed ID: 21570569
    [No Abstract]   [Full Text] [Related]  

  • 18. Case Records of the Massachusetts General Hospital: Case 22-2013: A 51-year-old woman with epistaxis and oral mucosal ulcers.
    Woo SB; Stone JH; Kraft S
    N Engl J Med; 2013 Jul; 369(3):265-74. PubMed ID: 23863054
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a role for the detection of autoantibodies in the clinical practice of treating infants with bullous pemphigoid? A case report.
    Brazzelli V; Grasso V; Bossi G; Borroni G
    Pediatr Dermatol; 2014; 31(6):748-9. PubMed ID: 23406459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mortality and clinical response of patients with bullous pemphigoid treated with rituximab.
    Yoo DS; Lee JH; Kim SC; Kim JH
    Br J Dermatol; 2021 Jul; 185(1):210-212. PubMed ID: 33657641
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.